, the peak concentration (C max ) is 31,308 ± 9,443 ng/ mL. The mean area under the time versus concentration curve (AUC) is AUC 0-5 hours 21,796 ± 5,490 h•ng/ mL and AUC 0-24 hours 22,267 ± 5,485 h•ng/mL with a clearance of 70.5 ± 17.9 L/h. The volume of distribution is 409 ± 76.7 L. The time to peak concentration (T max ) occurs at 0.42 hours; the terminal half-life (t ½ ) is 4.07 ± 0.39 hours. 8 Following a 30-minute infusion of 1,000 mg/ m 2 , the peak concentration (C max ) is 127.6 ± 43.5 μmol/L. The AUC is 102 ± 58.3 h•μmol/L. The steady state volume of distribution is 22.6 ± 9.7 L/m 2 with a clearance of 41.1 ± 22.2 L/h/m 2 . 4 In another report following a 30-minute infusion of 1,000 mg/m 2 , the peak concentration (C max ) is 32,124 ± 9,128 ng/mL. The AUC is 9,990 ± 3,420 ng•h/mL. 7 The steady state volume of distribution is 113.9 ± 60.9 L/m 2 with a clearance of 110.5 ± 34.4 L/h/m 2 . 7 The half-life (t ½ ) is 1 ± 0.1 hour. 4 Belinostat is metabolized in the liver, primarily through glucuronidation by UGT1A1 and, to a lesser extent, oxidation by CYP2A6, CYP2C9, and CYP3A4. About 40% of a dose is excreted renally, primarily as metabolites, with 0.2% to 2% excreted as the parent drug. 7 Selected therapeutic regimens of belinostat appear in Table 1 
MECHANISM OF ACTION
Idelalisib is an oral phosphatidylinositol-3-kinase (PI3-K) inhibitor that is highly specifi c for the δ isoform.
10-14 The PI3-K δ pathway demonstrates a substantial role in B-cell receptor signaling as well as B-lymphocyte expression. 10, 11 B-cell malignancies have demonstrated an up-regulation of the PI3-K-δ kinase. Inhibition of the PI3-K pathway decreases cell proliferation, motility, and survival.
11,13

PHARMCOKINETICS
Idelalisib displays linear pharmacokinetics.
11
Twice daily dosing maintained a continuous plasma exposure when daily dosing did not. 10 The T max occurs 1.5 hours after oral administration; the terminal elimination t ½ is 8.2 hours. 15 Steady state is achieved at day 8. 10, 11, 14 Administration with a high-fat meal increases the AUC about 40%. Idelalisib is highly (>84%) bound to plasma proteins, with a steady-state volume of distribution (V d ) of 23 L and a clearance of 14.9 L/h. The drug is metabolized primarily by aldehyde oxidase and CYP3 to a major metabolite (GS-563117), with minor metabolism by UGT1A4. Idelalisib is eliminated 78% in the feces and 14% in the urine. GS-563117 is 49% excreted in the urine and 44% in the feces. 15 Selected therapeutic regimen of idelalisib is shown in Table 2 ; headache (all grades) 10% to 20%, 13, 14 (grade 3 or 4) 1% 13 ; insomnia (all grades) 8% to 10%.
C. Constitutional: Asthenia (all grades) 11% to 33%, 13, 14 (grade 3 or 4) 2% 13 ; chills (all grades) 8% to 20% 11 ; fatigue (all grades) 20% to 50%, 11, 13, 14 (grade 3 or 4) 2%
13
; night sweats (all grades) 10% to 11% 11, 13 ; pyrexia (all grades) 17% to 50%, 11, 13, 14 (grade 3 or 4) 2%
; weight loss (all grades) 14% to 17%. 13, 14 D. Dermatologic: Rash (all grades) 13% to 40%, 11, 13, 14 (grade 3 or 4) 2% to 20%. 
13,14
